
    
      This dose-escalation study will examine HLD100 in 24 subjects.

      The subjects (n=24) will be tested with HLD100 in ascending doses from 10mg up to 40mg.

      This study will be divided into several phases: Screening, Active Treatment and Follow-Up.
      All visits have a 2 day window to allow for scheduling.
    
  